Shares of Astex Pharmaceuticals ($ASTX) got hammered yesterday after regulators turned a skeptical eye on Eisai’s request for an expanded use of Dacogen, a leukemia-related drug the biotech licensed to Eisai.
Ahead of tomorrow’s scheduled FDA panel rev…
Archive for the ‘acute lymphoblastic leukemia’ Category
Astex hammered after regulators diss Dacogen application
February 8th, 2012 
John Carroll 
Posted in acute lymphoblastic leukemia, Astex Therapeutics, Blog, Companies, Dacogen, Diagnostics, Eisai, Funding, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, Videos 
Tags: biotech food social media 
Comments OffUPDATED: Amgen scoops up Micromet tumor-fighting pipeline for $1.2B
January 26th, 2012 John Carroll Not to be left out of the M&A rush, Amgen said this morning that it will buy German/U.S. cancer drug developer Micromet ($MITI) for $1.16 billion in cash. At $11 a share, the deal gives its investors a 33% premium on yesterday’s close.
Amgen ($AMGN…
Posted in acute lymphoblastic leukemia, Amgen, blinatumomab, Blog, Companies, Diagnostics, Funding, Medical Devices, Medical Supply, Mergers and Acquisitions, Micromet, Pharmaceuticals, Startups, Universities, Videos Tags: biotech food social media Comments OffFDA stamps approval on Eusa Pharma’s orphan leukemia drug
November 18th, 2011 Ryan McBride U.S. regulators have given a market green light for Eusa Pharma’s enzyme drug Erwinaze for a subset of patients with acute lymphoblastic leukemia who have immune reactions to an existing version of the therapy made with E. coli, the company said today….
Posted in acute lymphoblastic leukemia, Blog, Companies, Diagnostics, FDA, Funding, Medical Devices, Medical Supply, orphan drug status, Pharmaceuticals, Startups, Universities, Videos Comments Off